GSK plc (LON:GSK)
London · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 73.11B |
| Revenue (ttm) | 32.17B |
| Net Income (ttm) | 5.49B |
| Shares Out | 4.01B |
| EPS (ttm) | 1.33 |
| PE Ratio | 13.71 |
| Forward PE | 10.16 |
| Dividend | 0.61 (3.35%) |
| Ex-Dividend Date | Nov 13, 2025 |
| Volume | 20,122,460 |
| Average Volume | 9,264,732 |
| Open | 1,805.00 |
| Previous Close | 1,812.50 |
| Day's Range | 1,798.50 - 2,057.70 |
| 52-Week Range | 1,242.50 - 2,057.70 |
| Beta | 0.23 |
| RSI | 56.05 |
| Earnings Date | Feb 4, 2026 |
About GSK plc
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It a... [Read more]
Financial Performance
In 2024, GSK plc's revenue was 31.38 billion, an increase of 3.46% compared to the previous year's 30.33 billion. Earnings were 2.58 billion, a decrease of -47.75%.
Financial StatementsNews
GSK Reduces Medicine Costs in New U.S. Agreement
GSK Reduces Medicine Costs in New U.S. Agreement
Nine pharmaceutical companies including Bristol-Myers Squibb, GSK and Merck agreed to lower the prices that certain federal government programs and patients pay
The companies, including Bristol-Myers Squibb, GSK and Merck, would avoid potential U.S. tariffs in return.
Trump strikes deal with US drugmakers to cut Medicaid medicine costs
Officials pledge ‘massive savings’ as companies agree to offer drugs at prices equal to those in other wealthy nations Donald Trump and nine major pharmaceutical companies on Friday announced deals th...
Nine of the largest pharma companies ink deals with Trump to lower drug prices
Several of the largest U.S. and European-based drugmakers inked deals with President Donald Trump to voluntarily sell their medications for less, as his administration pushes to link the nation's drug...
GSK Deal Is Key Validation For CAMP4's Drug Discovery Platform: Analyst
CAMP4 Therapeutics Corporation (NASDAQ: CAMP) on Thursday entered into a strategic research, collaboration, and license agreement with GSK Plc (NYSE: GSK). The collaboration aims to identify and dev...
GSK (GSK) Resubmits New Drug Application for Antibiotic
GSK (GSK) Resubmits New Drug Application for Antibiotic
GSK: 2026 Looks Good
A Look Into GSK Inc's Price Over Earnings
In the current market session, GSK Inc. (NYSE: GSK) stock price is at $48.55, after a 0.33% decrease. However, over the past month, the company's stock spiked by 5.29% , and in the past year, by 44.4...
White House Readies Drug Price Deals With AbbVie, Novartis, Roche
AbbVie Inc. (NYSE: ABBV) and several other drugmakers are reportedly expected to announce agreements with the U.S. government on Friday to cut select prescription drug prices and comply with addition...
CAMP4 Therapeutics Teams With GSK On ASO Drug Candidates
(RTTNews) - CAMP4 Therapeutics Corporation (CAMP) on Thursday said it has entered into a strategic research, collaboration and license agreement with GSK to develop antisense oligonucleotide (ASO) dru...
GSK Gains Approval for New Asthma Treatment, Boosting Stock
GSK Gains Approval for New Asthma Treatment, Boosting Stock
GSK's Exdensur Gets FDA Nod for Severe Asthma Treatment
GSK secures FDA approval for Exdensur, the first twice-yearly biologic for treating severe asthma with an eosinophilic phenotype.
GSK's Asthma Drug Exdensur Gains FDA Approval, Boosting Growth Prospects
GSK's Asthma Drug Exdensur Gains FDA Approval, Boosting Growth Prospects
GSK's Asthma Drug Gets U.S. Greenlight--$4 Billion Blockbuster in the Making?
GSK's Asthma Drug Gets U.S. Greenlight--$4 Billion Blockbuster in the Making?
(EDIT) GSK Gains FDA Approval for Exdensur in Severe Eosinophilic Asthma
(EDIT) GSK Gains FDA Approval for Exdensur in Severe Eosinophilic Asthma
GSK (GSK) Gains FDA Approval for Exdensur in Asthma Treatment
GSK (GSK) Gains FDA Approval for Exdensur in Asthma Treatment
GSK wins FDA approval for Exdensur in severe eosinophilic asthma
Understood. Please provide the article for which you would like a meta description.
FDA Approves GSK's Exdensur For Severe Eosinophilic Asthma In Patients 12 And Older
(RTTNews) - GSK plc (GSK, GSK.L) announced that the US Food and Drug Administration approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment of severe asthma characterised by an eosinop...
Exdensur (depemokimab) approved by US FDA for the treatment of severe asthma
PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment of sev...
FDA Approves GSK's Exdensur for Severe Asthma Treatment
FDA Approves GSK's Exdensur for Severe Asthma Treatment
US FDA approves GSK's twice-yearly asthma drug
The U.S. Food and Drug Administration has approved GSK's add-on drug to treat asthma and a chronic inflammatory sinus condition, the drugmaker said on Tuesday, paving the way for a less frequently dos...
GSK Secures UK Approval for Exdensur in Asthma and Rhinosinusitis Treatments
GSK Secures UK Approval for Exdensur in Asthma and Rhinosinusitis Treatments
UK approves GSK's twice-yearly asthma drug
UK's health regulator on Monday approved GSK's twice-yearly drug for use as an add-on treatment for asthma in patients aged 12 and older, as well as for a chronic inflammatory sinus condition in adult...
GSK's Nucala for COPD and Depemokimab for Asthma Get CHMP Nod in EU
GSK gets CHMP backing for Nucala in COPD and depemokimab in asthma, setting up possible Europe approvals in 2026 for IL-5 therapies.
Dividend Income: Lanny's October 2025 Summary
In October, we (my wife and I) received a dividend income total of $3,948.78. Crushing it for an off-month – thanks to Vanguard (VOO) and Fidelity (FXAIX) for paying in October. We had quite a few div...